 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...5859606162636465666768...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: DORO: Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab (clinicaltrials.gov) - Jan 28, 2016
P4, N=120, Recruiting, Sponsor: Prof. Dr. Antonia M. Joussen
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: UNRAVEL: UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jan 27, 2016
P4, N=195, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed
- || acrizanib (LHA510) / Novartis
Trial primary completion date: LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration (clinicaltrials.gov) - Jan 26, 2016
P2, N=70, Recruiting, Sponsor: Alcon, a Novartis Company
Recruiting --> Completed Trial primary completion date: May 2016 --> Sep 2016
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date, Monotherapy: Stereotactic Radiotherapy for Wet AMD (STAR) (clinicaltrials.gov) - Jan 25, 2016
P3, N=411, Recruiting, Sponsor: King's College Hospital NHS Trust
Trial primary completion date: May 2016 --> Sep 2016 Trial primary completion date: Dec 2016 --> May 2019
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: VITCLEAR: A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=120, Recruiting, Sponsor: King's College Hospital NHS Trust
Trial primary completion date: Dec 2016 --> May 2019 Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial primary completion date: Noctura400 Treatment for Diabetic Retinopathy (CANDLE) (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=240, Recruiting, Sponsor: PolyPhotonix Medical
Trial primary completion date: Dec 2015 --> Dec 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Dec 2016
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change: ReCaLL: Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - Jan 22, 2016
P4, N=25, Active, not recruiting, Sponsor: GWT-TUD GmbH
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Dec 2016 Recruiting --> Active, not recruiting | N=50 --> 25
- |||| Lucentis (ranibizumab) / Roche, Novartis
Clinical protocol, Trial primary completion date: ECLIPSE: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (clinicaltrials.gov) - Jan 19, 2016
P3, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=50 --> 25 Trial primary completion date: Sep 2017 --> Dec 2018
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (clinicaltrials.gov) - Jan 19, 2016
P3, N=649, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2017 --> Dec 2018 Active, not recruiting --> Completed
- |||| Rayoqta (abicipar pegol) / Molecular Partners
Trial primary completion date: SEQUOIA: Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jan 17, 2016
P3, N=900, Recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Trial primary completion date: Aug 2018 --> May 2019
- |||| Rayoqta (abicipar pegol) / Molecular Partners
Trial primary completion date: CDER: A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jan 17, 2016
P3, N=900, Recruiting, Sponsor: Allergan
Trial primary completion date: Aug 2018 --> May 2019 Trial primary completion date: Aug 2018 --> May 2019
- PAN-90806 / PanOptica
Trial primary completion date: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Jan 17, 2016
P1, N=50, Active, not recruiting, Sponsor: PanOptica, Inc.
Trial primary completion date: Aug 2018 --> May 2019 Trial primary completion date: Apr 2017 --> Apr 2016
- ||||| Avegra (bevacizumab biosimilar) / Biocad
Trial initiation date, Trial primary completion date: GALATIR: Safety and Efficacy Study of BCD-021 Compared to Lucentis (clinicaltrials.gov) - Jan 15, 2016
P3, N=108, Not yet recruiting, Sponsor: Biocad
Trial primary completion date: Apr 2017 --> Apr 2016 Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: Dec 2016 --> Dec 2017
- ||||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Enrollment closed: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov) - Jan 15, 2016
P3, N=456, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: DRAGON: Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) (clinicaltrials.gov) - Jan 15, 2016
P4, N=333, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | PF582 (ranibizumab biosimilar) / Ligand
Trial completion: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) - Jan 15, 2016
P1/2, N=25, Completed, Sponsor: Pfenex, Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study (clinicaltrials.gov) - Jan 11, 2016
P4, N=50, Not yet recruiting, Sponsor: St. Michael's Hospital, Toronto
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jan 6, 2016
P4, N=20, Completed, Sponsor: Instituto de Olhos de Goiania
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma (clinicaltrials.gov) - Jan 6, 2016
P4, N=18, Completed, Sponsor: Ruijin Hospital
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD (clinicaltrials.gov) - Jan 5, 2016
P=N/A, N=30, Active, not recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema (clinicaltrials.gov) - Jan 4, 2016
P1, N=41, Completed, Sponsor: Vitreous -Retina- Macula Consultants of New York
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov) - Dec 31, 2015
P1, N=0, Withdrawn, Sponsor: Vitreous -Retina- Macula Consultants of New York
Active, not recruiting --> Completed N=15 --> 0
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) (clinicaltrials.gov) - Dec 31, 2015
P1/2, N=9, Completed, Sponsor: Vitreous -Retina- Macula Consultants of New York
N=15 --> 0 Active, not recruiting --> Completed | N=30 --> 9
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: RainbowExt: Rainbow Extension Study (clinicaltrials.gov) - Dec 29, 2015
P3, N=300, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis (clinicaltrials.gov) - Dec 29, 2015
P3, N=2, Completed, Sponsor: Instituto de Olhos de Goiania
- | Rayoqta (abicipar pegol) / Molecular Partners
Trial completion: A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Dec 21, 2015
P2, N=25, Completed, Sponsor: Allergan
Active, not recruiting --> Completed | N=30 --> 9 Recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: CANARI: CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab (clinicaltrials.gov) - Dec 18, 2015
P4, N=172, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Phase II Combination Steroid and Anti-VEGF for Persistent DME (clinicaltrials.gov) - Dec 17, 2015
P2, N=125, Recruiting, Sponsor: Diabetic Retinopathy Clinical Research Network
Recruiting --> Completed Trial primary completion date: Jan 2016 --> Dec 2016
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: ORION: Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion (clinicaltrials.gov) - Dec 14, 2015
P4, N=45, Recruiting, Sponsor: Valley Retina Institute
Trial primary completion date: Jan 2016 --> Dec 2016 Trial primary completion date: May 2014 --> May 2016
- LKA651 / Novartis, MorphoSys
Enrollment change, Trial withdrawal: A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Dec 11, 2015
P1, N=0, Withdrawn, Sponsor: Alcon Research
Trial primary completion date: May 2014 --> May 2016 N=72 --> 0 | Not yet recruiting --> Withdrawn
- PAN-90806 / PanOptica
Enrollment closed, Trial primary completion date: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Dec 11, 2015
P1, N=50, Active, not recruiting, Sponsor: PanOptica, Inc.
N=72 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Apr 2017
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: SwapTwo: Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab (clinicaltrials.gov) - Dec 10, 2015
P4, N=20, Recruiting, Sponsor: Rishi Singh
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Apr 2017 Not yet recruiting --> Recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (clinicaltrials.gov) - Dec 5, 2015
P3, N=240, Not yet recruiting, Sponsor: JHSPH Center for Clinical Trials
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study (clinicaltrials.gov) - Dec 4, 2015
P2, N=30, Active, not recruiting, Sponsor: University Hospital, Bonn
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma, Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date, Trial primary completion date: Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study (clinicaltrials.gov) - Dec 3, 2015
P2, N=66, Not yet recruiting, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting Initiation date: Oct 2015 --> Feb 2016 | Trial primary completion date: Apr 2017 --> Feb 2018
- | Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion (clinicaltrials.gov) - Nov 25, 2015
P1/2, N=20, Completed, Sponsor: Ohr Pharmaceutical Inc.
- Cimerli (ranibizumab-eqrn) / Amneal, Formycon, Coherus Biosci, Teva
New P3 trial: COLUMBUS-AMD: Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Nov 24, 2015
P3, N=0, Not yet recruiting, Sponsor: Bioeq GmbH
- || LKA651 / Novartis, MorphoSys
Trial primary completion date: A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Nov 21, 2015
P1, N=72, Not yet recruiting, Sponsor: Alcon Research
Initiation date: Oct 2015 --> Feb 2016 | Trial primary completion date: Apr 2017 --> Feb 2018 Trial primary completion date: Mar 2017 --> Jun 2017
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change, Trial primary completion date: RVOFV: Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision (clinicaltrials.gov) - Nov 19, 2015
P4, N=19, Active, not recruiting, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Mar 2017 --> Jun 2017 Recruiting --> Active, not recruiting | N=40 --> 19 | Trial primary completion date: Dec 2015 --> Jul 2016
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (clinicaltrials.gov) - Nov 17, 2015
P3, N=300, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=40 --> 19 | Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Jul 2017 --> Nov 2017
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: OLIMPIC: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (clinicaltrials.gov) - Nov 17, 2015
P3, N=200, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2017 --> Nov 2017 Recruiting --> Active, not recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: CAN-TREAT: Canadian Treat and Extend Analysis Trial With Ranibizumab (clinicaltrials.gov) - Nov 9, 2015
P=N/A, N=580, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: May 2017 --> Jun 2018
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema (clinicaltrials.gov) - Nov 3, 2015
P=N/A, N=30, Recruiting, Sponsor: Kagawa University
Trial primary completion date: May 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial primary completion date: Liberty: Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Oct 30, 2015
P4, N=60, Active, not recruiting, Sponsor: Retinal Consultants of Arizona
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Dec 2015
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: WAVE: Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion (clinicaltrials.gov) - Oct 30, 2015
P4, N=30, Completed, Sponsor: Charles C Wykoff, PhD, MD
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Dec 2015 Active, not recruiting --> Completed
- | Fovista (pegpleranib) / Roche, Astellas
New P1 trial: An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 30, 2015
P1, N=25, Active, not recruiting, Sponsor: Retinal Consultants of Arizona
- || Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change: OCEAN: Observation of Treatment Patterns With Lucentis in Approved Indications (clinicaltrials.gov) - Oct 28, 2015
P=N/A, N=6072, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=4500 --> 6072
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial initiation date: PROTECT: Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 27, 2015
P1/2, N=88, Recruiting, Sponsor: Leonard Feiner, MD, PhD
Recruiting --> Active, not recruiting | N=4500 --> 6072 Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> May 2015
- PAN-90806 / PanOptica
Trial primary completion date: Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD (clinicaltrials.gov) - Oct 22, 2015
P1, N=50, Recruiting, Sponsor: PanOptica, Inc.
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> May 2015 Trial primary completion date: Sep 2015 --> Mar 2016
- Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date, Trial suspension, Trial primary completion date: Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (clinicaltrials.gov) - Oct 22, 2015
P4, N=40, Suspended, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2015 --> Mar 2016 Initiation date: Mar 2015 --> Oct 2015 | Not yet recruiting --> Suspended | Trial primary completion date: May 2016 --> Oct 2016